Tg(Eef1a1-MYC/PGR*,-HRAS/ESR1*)1Rdl
Transgene Detail

Summary

• Symbol: Tg(Eef1a1-MYC/PGR*,-HRAS/ESR1*)1Rdl
• Name: transgene insertion 1, Roberto Di Lauro
• MGI ID: MGI:5699743
• Synonyms: Tg(Eef1a1-cMycPR-ERHRas), Tg(Eef1a1-MYC/PGR,-HRAS/ESR1*)1Rdl
• Transgene: Tg(Eef1a1-MYC/PGR*,-HRAS/ESR1*)1Rdl Location: unknown
• Alliance: Tg(Eef1a1-MYC/PGR*,-HRAS/ESR1*)1Rdl page

Transgene origin

• Strain of Origin: 129/Sv

Transgene description

• Transgene Type: Transgenic (Conditional ready, Inducible, Inserted expressed sequence)
• Inducer: mifepristone and tamoxifen
• Mutation: Insertion
• Tg(Eef1a1-MYC/PGR*,-HRAS/ESR1*)1Rdl expresses 2 genes
  Transgene expresses:
  

  Organism

  Expressed Gene

  Homolog in Mouse

  Note

  human

  HRAS (3265)

  Hras	(MGI:96224)

  Transgene expresses a HRAS/tamoxifen-responsive estrogen receptor ligand-binding domain fusion protein.

  human

  MYC (4609)

  Bmyc	(MGI:88184)
  Myc	(MGI:97250)

  Transgene expresses a MYC/mifepristone- (RU486-) responsive progesterone receptor (hPR891) ligand-binding domain fusion protein.

• Mutation details: The human MYC and (mutant) HRAS oncogenes can be conditionally expressed from this transgene, and activity of either or both proteins can be induced. The transgene contains the promoter of the ubiquitously expressed eukaryotic translation elongation factor 1 alpha 1 (Eef1a1) gene followed by: a loxP-flanked STOP sequence; a cDNA encoding the human v-myc avian myelocytomatosis viral oncogene homolog (MYC) protein fused to a mutated ligand-binding domain of the human progesterone receptor (hPR891) that binds to mifepristone (RU486), but not to endogenous progesterone; an internal ribosomal entry site (IRES); and a cDNA encoding the oncogenic G12V (glycine to valine at amino acid position 12) mutant human HRAS protein fused to a mutated estrogen receptor binding domain that binds to tamoxifen, but not to endogenous estrogen. Crossing mice bearing this transgene with mice expressing Cre recombinase will delete the STOP sequence, allowing transcription to proceed in the tissues or cell types where Cre is expressed. Treatment of the doubly transgenic mice with RU486 and/or tamoxifen will then activate the MYC and/or mutant HRAS protein, respectively, in those tissues/cell types. (J:227110)

Find Mice (IMSR)

• Mouse strains and cell lines available from the International Mouse Strain Resource (IMSR)
• Carrying this Mutation: Mouse Strains: 1 strain available Cell Lines: 0 lines available

References

• Original: J:227110 Modica TM, Ph.D. Thesis, Open University: A mouse model to study inducible oncogene cooperation in vivo. eThOS. 2012
• All: 1 reference(s)